관련문헌 등
·Hematology: Basic Principles and Practice 7th edition (2018)> Chapter 69: Essential Thrombocythemia
·Consultative Hemostasis and Thrombosis, 4th edition (2019) ch. 19, 346-373
·NCCN Guidelines, Myeloproliferative Neoplasms Version 2.2019, Oct 29, 2018
·World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017
·PVSG and WHO vs European Clinical, Molecular and Pathological Criteria for prefibrotic myeloproliferative neoplasms World J Hematol 2013 August 6; 2(3): 71-88
·Guidelines for the management of myeloproliferative neoplasms Korean J Intern Med 2015;30:771-788
·ESMO guidelines, Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 26 (Supplement 5): v85？v99, 2015
·Claire N. Harrison et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia N Engl J Med 2005;353:33-45
·Heinz Gisslinger et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial Blood. 2013;121(10):1720-1728
·Birgegard G et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. 2018 Jan;103(1):51-60
·Mela Osorio, M. J. et al. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur. J. Haematol. 96, 435？442 (2016)
·Tefferi et al. Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal (2018) 8:2